GKOS - NYSE
Glaukos Corporation
$113.64
+2.6%Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
At a Glance
Live Snapshotgkos
Total Debt
Last Annual Value
139.64M
3-Year CAGR
-29%
5-Year CAGR
-12%
10-Year CAGR
31%
Glaukos Corporation Competitors Analysis of Total Debt
| Company | Total Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Glaukos Corporation NYSE:GKOS | 139.64M | -28.6% | -18.3% | N/A | |
 Teleflex Incorporated NYSE:TFX | 2.73B | 12.3% | 6.8% | 10.2% | |
 TransMedics Group, Inc. NASDAQ:TMDX | 469.69M | -3.1% | 60.7% | 49.5% | |
 Oscar Health, Inc. NYSE:OSCR | 430.10M | 12.9% | N/A | N/A | |
 Arcellx, Inc. NASDAQ:ACLX | 96.26M | -0.5% | N/A | N/A | |
 Alkermes plc NASDAQ:ALKS | 70.00M | -42.7% | -30.0% | -13.1% | |
 Bruker Corporation NASDAQ:BRKR | 2.04B | 14.0% | 7.9% | 17.4% | |
 Arrowhead Pharmaceuticals, Inc. NASDAQ:ARWR | 366.28M | -1.5% | 70.3% | 63.2% | |
 iRhythm Technologies, Inc. NASDAQ:IRTC | 731.18M | 77.9% | 44.1% | 36.6% | |
 Merit Medical Systems, Inc. NASDAQ:MMSI | 898.23M | 0.3% | 22.5% | 10.7% |
Glaukos Corporation Fair Value Envelope
Related Guides
Continue your GKOS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.